Literature DB >> 18475589

Analysis of Signals Leading to Differentiation of Immature HL-60 after Administration of IL-4.

S Vassiliadis1.   

Abstract

Treatment of acute myeloid leukaemia (AML) cells with differentiation agents leads not only to the acquisition of normal phenotypes but also contributes to the understanding of special immuno-haematology issues. For instance, induction of HLA-DR antigens on human promyelocytic leukaemia HL-60 cells by interleukin-4 (IL-4) is of pivotal importance in immunology not only because class II expression is prerequisite to antigen recognition and response but also because IL-4 participates in a plethora of inflammatory or non-inflammatory reactions. At the same time, the same observation coupled with an increase in Mac-1, mature monocyte marker, is revealing ways to haematologists for converting malignant cases to normal situations. Based on previous reports that HLA-DR induction by IL-4 in the HL-60 system is mediated via the G-protein system (p21(ras)), this study was undertaken in order to define the intermediate signalling steps followed by this agent from the moment it is added to cultures to the differentiated cellular form obtained. It is proposed that IL-4 increases p21(ras) which in turn suppresses the HL-60 cells' p34(cdc2) constitutive expression. This inhibition appears to be responsible for the subsequently.observed cessation ofgrowth. Concomitant to decreased cellular proliferation, HI-DR antigen expression increases, a finding that matches the initially mentioned induction of p21(ras) since its inhibition abolishes HI-DR upregulation.

Entities:  

Year:  1994        PMID: 18475589      PMCID: PMC2365590          DOI: 10.1155/S096293519400058X

Source DB:  PubMed          Journal:  Mediators Inflamm        ISSN: 0962-9351            Impact factor:   4.711


  14 in total

Review 1.  Interleukin-4: a prototypic immunoregulatory lymphokine.

Authors:  W E Paul
Journal:  Blood       Date:  1991-05-01       Impact factor: 22.113

2.  Expression and capping of a proliferation-associated surface membrane p34 kDa antigen on different human hematopoietic cell lines.

Authors:  R J Streck; E L Hurley; J L Pauly
Journal:  J Leukoc Biol       Date:  1991-08       Impact factor: 4.962

Review 3.  Early events in T-cell maturation.

Authors:  B Adkins; C Mueller; C Y Okada; R A Reichert; I L Weissman; G J Spangrude
Journal:  Annu Rev Immunol       Date:  1987       Impact factor: 28.527

Review 4.  The developmental biology of T lymphocytes.

Authors:  H von Boehmer
Journal:  Annu Rev Immunol       Date:  1988       Impact factor: 28.527

Review 5.  The HL-60 promyelocytic leukemia cell line: proliferation, differentiation, and cellular oncogene expression.

Authors:  S J Collins
Journal:  Blood       Date:  1987-11       Impact factor: 22.113

6.  Mechanisms of p34cdc2 regulation.

Authors:  S Atherton-Fessler; L L Parker; R L Geahlen; H Piwnica-Worms
Journal:  Mol Cell Biol       Date:  1993-03       Impact factor: 4.272

7.  The role of IL-4 in human myeloid leukemia: stimulation of RNA synthesis and transduction of differentiation signals through an IL-4 receptor leads to functional and HLA positive HL-60 cells.

Authors:  S Vassiliadis; N Kyrpides; J Papamatheakis
Journal:  Leuk Lymphoma       Date:  1992-06

8.  The p21ras protein as an intermediate signaling molecule in the IL-4-induced HLA-DR expression on normal and leukemic human myeloid cells.

Authors:  S Vassiliadis; J Papamatheakis
Journal:  Cell Immunol       Date:  1992-07       Impact factor: 4.868

9.  A family of human cdc2-related protein kinases.

Authors:  M Meyerson; G H Enders; C L Wu; L K Su; C Gorka; C Nelson; E Harlow; L H Tsai
Journal:  EMBO J       Date:  1992-08       Impact factor: 11.598

10.  Investigation of intracellular signals generated by gamma-interferon and IL-4 leading to the induction of class II antigen expression.

Authors:  S Vassiliadis; N Kyrpides; D Stravopodis; M Grigoriou; I Athanassakis; J Papamatheakis
Journal:  Mediators Inflamm       Date:  1993       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.